Is Syncom Formul. overvalued or undervalued?

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, indicating that while the company has a relatively low growth expectation, its valuation remains high compared to its earnings.
In comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma. Inds., which stands at 36.49, and Divi's Lab., which is at 69.65, both categorized as expensive to very expensive. Conversely, Cipla, which is rated attractive, has a PE ratio of 22.72, suggesting that Syncom Formul. may not be as competitively priced within its sector. The stock has underperformed the Sensex over the past year, with a return of -20.15% compared to the Sensex's 9.00%, reinforcing the notion that it is currently overvalued.